Text this: Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

 ______     ______    _  _      ___              
|      \\  /_   _//  | \| ||   / _ \\    ____    
|  --  //   -| ||-   |  ' ||  / //\ \\  |    \\  
|  --  \\   _| ||_   | .  || |  ___  || | [] ||  
|______//  /_____//  |_|\_|| |_||  |_|| |  __//  
`------`   `-----`   `-` -`  `-`   `-`  |_|`-`   
                                        `-`